Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab and Radiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Not Eligible for Cisplatin Therapy

NCT02609503 is registered in ClinicalTrials.gov with UNC Lineberger Comprehensive Cancer Center as lead sponsor.

NCT NCT02609503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02609503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab and Radiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Not Eligible for Cisplatin Therapy
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
May 16, 2016
Completion date
November 20, 2023
Enrollment
29 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer